Dynavax Technologies Co. (NASDAQ:DVAX) Position Decreased by Fisher Asset Management LLC

Fisher Asset Management LLC cut its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 16.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,389,950 shares of the biopharmaceutical company’s stock after selling 272,072 shares during the period. Fisher Asset Management LLC owned approximately 1.08% of Dynavax Technologies worth $19,432,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Dynavax Technologies by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 9,146,891 shares of the biopharmaceutical company’s stock valued at $135,100,000 after purchasing an additional 270,730 shares during the period. Blair William & Co. IL boosted its position in Dynavax Technologies by 0.6% during the 3rd quarter. Blair William & Co. IL now owns 2,470,191 shares of the biopharmaceutical company’s stock worth $36,485,000 after acquiring an additional 15,059 shares during the period. Northern Trust Corp grew its stake in Dynavax Technologies by 1.7% during the 3rd quarter. Northern Trust Corp now owns 1,446,728 shares of the biopharmaceutical company’s stock valued at $21,368,000 after acquiring an additional 23,623 shares in the last quarter. Eventide Asset Management LLC grew its stake in Dynavax Technologies by 38.9% during the 3rd quarter. Eventide Asset Management LLC now owns 1,425,000 shares of the biopharmaceutical company’s stock valued at $21,047,000 after acquiring an additional 398,914 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Dynavax Technologies by 20.5% during the third quarter. Bank of New York Mellon Corp now owns 1,359,729 shares of the biopharmaceutical company’s stock worth $20,083,000 after purchasing an additional 231,731 shares during the period. 96.96% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CAO Justin Burgess sold 20,526 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $12.78, for a total value of $262,322.28. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 2.98% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on DVAX shares. The Goldman Sachs Group began coverage on shares of Dynavax Technologies in a research report on Thursday, February 1st. They issued a “neutral” rating and a $20.00 target price for the company. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 23rd. Finally, StockNews.com lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Friday, April 26th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $25.00.

Dynavax Technologies Trading Up 0.2 %

Shares of DVAX stock opened at $11.74 on Monday. The business’s 50 day moving average is $12.14 and its two-hundred day moving average is $13.07. The company has a quick ratio of 12.96, a current ratio of 13.81 and a debt-to-equity ratio of 0.41. Dynavax Technologies Co. has a 12 month low of $10.57 and a 12 month high of $15.15. The company has a market cap of $1.54 billion, a PE ratio of -195.63 and a beta of 1.30.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.